Financial Performance - Operating revenue decreased by 43.28% to CNY 27,428,266.45 year-on-year[10] - Net profit attributable to shareholders dropped by 81.25% to CNY 2,935,721.18 compared to the same period last year[10] - Cash flow from operating activities showed a net outflow of CNY -9,947,732.55, a decrease of 92.33% year-on-year[10] - Total operating revenue for Q1 2024 was CNY 27,428,266.45, a decrease of 43.2% compared to CNY 48,355,904.46 in Q1 2023[39] - Net profit for Q1 2024 was CNY 3,132,087.56, a decline of 83.2% from CNY 18,570,360.41 in Q1 2023[40] - Total profit for Q1 2024 was CNY 3,222,796.82, a significant decline from CNY 25,091,514.56 in Q1 2023[42] Assets and Liabilities - Total assets increased by 2.39% to CNY 625,823,172.64 compared to the end of last year[10] - Total current assets as of March 31, 2024, amounted to ¥485,042,394.82, a decrease of 3.4% from ¥500,099,224.08 on December 31, 2023[32] - Total non-current assets rose to ¥140,780,777.82, an increase of 26.8% compared to ¥111,143,790.88[33] - Total liabilities amounted to ¥56,230,029.08, compared to ¥44,721,796.94, indicating a growth of 25.7%[34] - Total current liabilities increased to ¥54,729,556.75, a rise of 29.0% from ¥42,485,404.25[34] - The debt-to-asset ratio for the consolidated entity rose to 8.98%, up from 7.33% at the end of the previous year[10] Cash Flow - Cash and cash equivalents increased to ¥159,618,680.60 from ¥129,280,366.78, representing a growth of 23.5%[32] - Cash flow from operating activities for Q1 2024 was negative at CNY -9,947,732.55, compared to CNY -5,172,226.30 in Q1 2023[45] - The net cash flow from operating activities was -9,159,946.17, compared to -9,325,708.15 in the previous year, indicating a slight improvement[47] - Total cash inflow from investment activities in Q1 2024 was CNY 257,540,721.48, with a net cash flow of CNY 41,587,256.58[45] - Cash inflow from investment activities was 257,540,721.48, compared to 8,761,904.76 in the previous year, showing a substantial increase[47] Shareholder Information - The total share capital of Ningbo New Zhi Biotechnology Co., Ltd. is 91,515,941 shares[18] - The number of shareholders holding more than 5% of shares is 10, with a total of 53,580,509 shares, accounting for 58.55% of total shares[19] - The company has repurchased 2,637,454 shares, which is 2.88% of the total share capital, with a total expenditure of 28,208,376.26 yuan[26] - The company plans to use repurchased shares for employee equity incentives, with a repurchase range of 2,400,000 to 3,800,000 shares[25] Research and Development - Research and development expenses increased by 44.73% to CNY 4,782,985.43, reflecting a commitment to innovation[12] - Research and development expenses for Q1 2024 were CNY 4,782,985.43, up from CNY 3,304,808.87 in Q1 2023, indicating a rise of 44.8%[39] Litigation and Commitments - The company has ongoing litigation with a cumulative amount of 6,944,600 yuan, representing 1.29% of the net assets at the end of the reporting period[23] - The company has not experienced any significant adverse impacts from ongoing litigation[23] - The company has fulfilled all disclosed commitments without any violations[27]
新芝生物(430685) - 2024 Q1 - 季度财报